Loading…
Pharmaceutical Contract Research, Development and Manufacturing Organization · NSE · period ending 2026-03-31
Loading chart…
✓ Core business is permissible and non-compliant income is 0.22% of revenue (limit 5%).
| Ratio | Value | Limit | Result |
|---|---|---|---|
| Interest-bearing debt / market cap | 0.62% | < 30% | Pass |
| Interest-bearing investments / market cap | 1.81% | < 30% | Pass |
The underlying figures and the filing citations they came from are available with a free account.
Sign up free0.22% of any dividend from SAILIFE should be given to charity. Calculate your amount →
Compliance watch: verdict re-verified against live market cap on 13 Jun 2026 · rechecked every 6 hours · filings reviewed quarterly.
SAILIFE is in a strong uptrend with double-digit gains across 1–6 months and price almost at its 52-week high. The 50-day above the 200-day is consistent with strong recent momentum, with no specific sector sentiment given to amplify or dampen this trend.
Computed from delayed price history and desk sentiment. Educational context only — not investment advice or a price prediction.